▎WuXiEdited by the Kant Content Team

AvenCell Therapeutics Announces $112 Million Series B Financing Led by Novo Holdings with Participation from F-Prime Capital, Eight Roads Ventures Japan, Piper Heartland Healthcare Capital, NYBC Ventures, and Founding Investor Blackstone Life Sciences

AvenCell is a clinical-stage cell therapy company focused on advancing controllable autologous and allogeneic CAR-T cell therapies. AvenCell is dedicated to treating difficult-to-cure cancers, with its core project centered on acute myeloid leukemia (AML), while also developing programs targeting other hematologic malignancies.AvenCell’s goal is to create allogeneic cells with persistence comparable to or stronger than autologous therapies, and to develop a universal and controllable chimeric antigen receptor.T cellsRemains active after infusion into the patient and can target different sites by adding different adaptor proteins.The combination of these two platforms has the potential to make cell production不受患者和靶点的限制, thereby significantly enhancing the potential for therapy scalability.

▲To learn more about the application of cutting-edge technologies in the biopharmaceutical industry, please long press and scan the QR code above to access "WuXi Live Studio" and watch live discussions and exciting replays on related topics.

References:

[1] AvenCell Raises $112 Million in Series B; Funding Led by Novo Holdings. Retrieved October 22, 2024 from https://avencell.com/avencell-raises-112-million-in-series-b-funding-led-by-novo-holdings/

Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange purposes only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article. This article is not a recommendation for treatment plans. If you need guidance on treatment options, please visit a regular hospital.

Copyright Statement: This article is from the content team of WuXi AppTec. Individuals are welcome to share it on their social media platforms, but unauthorized reproduction by media or institutions in any form to other platforms is prohibited. For authorization to reproduce, please reply with "reprint" on the WeChat Official Account of "WuXi AppTec" to obtain reprint guidelines.